sclerodermatous


Also found in: Dictionary, Thesaurus, Encyclopedia.

scle·ro·der·ma·tous

(sklē'rō-der'mă-tŭs),
Marked by, or resembling, scleroderma.

sclerodermatous

(sklîr′ə-dûr′mə-təs)
adj.
1. Of, relating to, or affected by scleroderma.
2. Zoology Having an outer covering of hard plates or bony scales.

scleroderma

(skler?a-der'ma) [Gr. skleros, hard, + derma, skin]
A chronic manifestation of progressive systemic sclerosis in which the skin is taut, firm, and edematous, limiting movement. sclerosis, progressive systemic; sclerodermatous, adjective

circumscribed scleroderma

Localized patches of linear sclerosis of the skin. There is no systemic involvement, and the course of the disease is usually benign.

scleroderma neonatorum

Sclerema neonatorum.
References in periodicals archive ?
Sclerodermatous lesions begin with indurated plaques with loss of skin markings and appendages causing pain and chronic ulceration, predisposing to generalized wasting and pyogenic infections of the skin.
The presence of both lichen sclerosus-like lesions and the histological findings of septal panniculitis in the disease process suggest that the sclerosis in sclerodermatous GVHD can start and affect any level of the skin and can extend to involve the complete dermis, the subcutis, and even the fascia.
Sclerodermatous cGVHD can give rise to reduced range of motion and secondary effects including loss of strength, endurance and functional capabilities.
Spontaneous resolution of sclerodermatous GVHD may occur.
Numerous treatments, including prednisone, azathioprine, penicillamine, CsA, methotrexate, MMF, thalidomide, clofazimine, anti-CD20 monoclonal antibody, ECP, phototherapy with bath PUVA, UVA1 or UVB, etretinate or various combinations, have been tried with varying success in sclerodermatous GVHD (2), (3), (5), (15-22).
In conclusion, sclerodermatous GVHD has a late onset and clinically may be quite disabling.
Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease.